ArticleiScience2026
Immune context and treatment timing associated with seizure freedom after rituximab in autoimmune limbic encephalitis.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Seizure freedom represents a clinically meaningful outcome in autoimmune limbic encephalitis (ALE). Rituximab (RTX) is commonly used, but the factors associated with seizure outcomes remain unclear. We conducted a retrospective single-center cohort study including 107 adults with ALE and seizures treated between 2005 and 2024. Patients were stratified by RTX treatment, treatment timing, cerebrospinal fluid (CSF) findings, and seizure outcome. The primary endpoint was seizure freedom for ≥12 months. Overall, 72/107 patients (70.6%) achieved seizure freedom, including 18 RTX-treated patients. Earlier RTX initiation (< 12 months) was numerically associated with higher seizure freedom rates than later treatment (77.8% vs. 37.5%). In RTX-treated patients, positive CSF immune findings were associated with seizure freedom (100% vs. 62.5%). Combining early RTX initiation and positive CSF findings was associated with increased odds of seizure freedom. In multivariable analysis, RTX treatment was not independently associated with seizure freedom. These exploratory findings require prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.